These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23108247)

  • 1. Brain metastasis: opportunity for drug development?
    Preusser M; Berghoff AS; Schadendorf D; Lin NU; Stupp R
    Curr Opin Neurol; 2012 Dec; 25(6):786-94. PubMed ID: 23108247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.
    Lombardi G; Di Stefano AL; Farina P; Zagonel V; Tabouret E
    Cancer Treat Rev; 2014 Sep; 40(8):951-9. PubMed ID: 24909312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases.
    Sandler A; Hirsh V; Reck M; von Pawel J; Akerley W; Johnson DH
    Lung Cancer; 2012 Oct; 78(1):1-7. PubMed ID: 22877947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.
    Jamal-Hanjani M; Spicer J
    Clin Cancer Res; 2012 Feb; 18(4):938-44. PubMed ID: 22167408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.
    Tomasello G; Bedard PL; de Azambuja E; Lossignol D; Devriendt D; Piccart-Gebhart MJ
    Crit Rev Oncol Hematol; 2010 Aug; 75(2):110-21. PubMed ID: 20004109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
    Franciosi V; Cocconi G; Michiara M; Di Costanzo F; Fosser V; Tonato M; Carlini P; Boni C; Di Sarra S
    Cancer; 1999 Apr; 85(7):1599-605. PubMed ID: 10193952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy for brain metastases.
    Davies MA
    Adv Pharmacol; 2012; 65():109-42. PubMed ID: 22959025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy in brain metastasis.
    Soffietti R; Trevisan E; Rudà R
    Curr Opin Oncol; 2012 Nov; 24(6):679-86. PubMed ID: 22820413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain metastases: pathobiology and emerging targeted therapies.
    Preusser M; Capper D; Ilhan-Mutlu A; Berghoff AS; Birner P; Bartsch R; Marosi C; Zielinski C; Mehta MP; Winkler F; Wick W; von Deimling A
    Acta Neuropathol; 2012 Feb; 123(2):205-22. PubMed ID: 22212630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic treatment in breast-cancer patients with brain metastasis.
    Arslan C; Dizdar O; Altundag K
    Expert Opin Pharmacother; 2010 May; 11(7):1089-100. PubMed ID: 20345334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases.
    Milas I; Komaki R; Hachiya T; Bubb RS; Ro JY; Langford L; Sawaya R; Putnam JB; Allen P; Cox JD; McDonnell TJ; Brock W; Hong WK; Roth JA; Milas L
    Clin Cancer Res; 2003 Mar; 9(3):1070-6. PubMed ID: 12631609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastases to the brain: current management perspectives.
    Nathoo N; Toms SA; Barnett GH
    Expert Rev Neurother; 2004 Jul; 4(4):633-40. PubMed ID: 15853582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
    Socinski MA
    Cancer Treat Rev; 2011 Dec; 37(8):611-7. PubMed ID: 21641723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
    Sangha R; Lara PN; Mack PC; Gandara DR
    Curr Opin Oncol; 2009 Mar; 21(2):116-23. PubMed ID: 19532012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases.
    DiLuna ML; King JT; Knisely JP; Chiang VL
    Cancer; 2007 Jan; 109(1):135-45. PubMed ID: 17133440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
    Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic therapy in nonsmall cell lung cancer.
    Gutierrez M; Giaccone G
    Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.
    Gabos Z; Sinha R; Hanson J; Chauhan N; Hugh J; Mackey JR; Abdulkarim B
    J Clin Oncol; 2006 Dec; 24(36):5658-63. PubMed ID: 17102066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.